Research programme: bispecific antibodies - I-Mab Biopharma/Shanghai Genechem
Latest Information Update: 06 Jun 2021
At a glance
- Originator I-MAB Biopharma; Shanghai Genechem
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer